Loading...
•
Dec 31, 2019
Nevro Q4 2019 Earnings Report
Nevro's Q4 2019 earnings report was released, showcasing revenue growth and strategic advancements.
Key Takeaways
Nevro Corp. reported a 6% increase in worldwide revenue for Q4 2019, reaching $114.4 million, with U.S. revenue up 7% to $97.9 million. The company launched Senza Omnia commercially in the U.S. and presented positive data from its Senza-PDN study.
Worldwide revenue increased by 6% year-over-year, reaching $114.4 million.
U.S. revenue grew by 7% compared to the prior year period, totaling $97.9 million.
U.S. patient trials and permanent implants grew by 17% and 20%, respectively.
Senza Omnia SCS System was commercially launched in the U.S.
Revenue by Geographic Location
Forward Guidance
Nevro reiterated its full year 2020 worldwide revenue to be in the range of $435 to $440 million. Gross margin is expected to be in the range of 69% to 70% and operating expenses are expected to be approximately $355 million, including litigation expenses. Adjusted EBITDA guidance of positive $3.0 to $10.0 million for the full year 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...